1. 1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. (23rd October 2018) Authors: Morelli, A M; Migliorino, M R; Morabito, A; Chiari, R; Grossi, F; Bordi, P; Di Costanzo, F; Delmonte, A; Romano, G; Misino, A; Scotti, V; Gregorc, V; Pisconti, S; Ceresoli, G L; Del Conte, A; Colantonio, I; Ciuffreda, L; Capelletto, E; Stura, I; Novello, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1440PRandomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type. (23rd October 2018) Authors: Grossi, F; Jaskiewicz, P; Pichon, E; Czyzewicz, G; Kowalski, D M; Ciuffreda, L; Garcia Gomez, R; Caruso, S; Bosch Barrera, J; Ta Thanh Minh, C; Gautier, S; Hervieu, H; Henriet, S; De Castro Jr, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗